{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:04:05Z","timestamp":1780074245924,"version":"3.54.0"},"reference-count":55,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background and Clinical Significance: Sarcomatoid renal cell carcinoma is a rare and highly aggressive variant of renal cell carcinoma, frequently associated with advanced-stage disease, early metastatic spread, and poor prognosis. Although immune checkpoint inhibitors have improved outcomes in metastatic renal cell carcinoma, particularly in tumors with sarcomatoid differentiation, they may also induce severe immune-related adverse events involving multiple organ systems. Case Presentation: We report the case of a 54-year-old woman with metastatic clear cell renal cell carcinoma with sarcomatoid differentiation, previously treated with nivolumab plus ipilimumab and subsequently with pazopanib, who was admitted with severe dehydration, repeated vomiting, marked asthenia, lower-limb-predominant muscle weakness, and inability to maintain orthostatism. Laboratory investigations revealed severe hyperkalemia, hyponatremia, hypoglycemia, anemia, thrombocytopenia, and prerenal acute kidney injury. The patient had a previous history of severe endocrine immune-related toxicity, including autoimmune hypophysitis and hypothyroidism, which had led to discontinuation of immunotherapy. Following fluid resuscitation, electrolyte correction, and supportive treatment, the metabolic abnormalities resolved and renal function improved significantly. Given the severity of the muscle weakness, a possible immune-mediated neuromuscular adverse event was also considered, although hyperkalemia remained a plausible contributing factor. Conclusions: This case highlights the complex interplay between prior immune checkpoint inhibitor exposure, endocrine dysfunction, metabolic decompensation, and possible neuromuscular involvement in metastatic sarcomatoid renal cell carcinoma. Early recognition, careful differential diagnosis, and multidisciplinary management are essential to prevent rapid clinical deterioration and optimize outcomes in patients with complex immune-related toxicities.<\/jats:p>","DOI":"10.3390\/diagnostics16111679","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:57:18Z","timestamp":1780070238000},"page":"1679","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Severe Metabolic Decompensation in Metastatic Sarcomatoid Renal Cell Carcinoma During Immune Checkpoint Inhibitor Therapy: A Case Report and Literature Review"],"prefix":"10.3390","volume":"16","author":[{"given":"Lorena","family":"Cium\u0103rnean","sequence":"first","affiliation":[{"name":"Department 2, Faculty of Nursing and Health Sciences, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, Republicii Street, No. 18, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4090-0164","authenticated-orcid":false,"given":"Cezara Andreea","family":"Gerdanovics","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, 4 th Medical Discipline, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, Republicii Street, No. 18, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4435-142X","authenticated-orcid":false,"given":"Olga Hilda","family":"Or\u0103\u0219an","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, 4 th Medical Discipline, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, Republicii Street, No. 18, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5185-9512","authenticated-orcid":false,"given":"Alexandru","family":"Gerdanovics","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, Victor Babe\u015f Street, No. 2-4, 400012 Cluj-Napoca, Romania"},{"name":"Clinical Rehabilitation Hospital, Viilor Street, No. 46-50, 400066 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoleta Valentina","family":"Leach","sequence":"additional","affiliation":[{"name":"Department 2, Faculty of Nursing and Health Sciences, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, Republicii Street, No. 18, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Para","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, 4 th Medical Discipline, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, Republicii Street, No. 18, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Bombonica","family":"Dogaru","sequence":"additional","affiliation":[{"name":"Clinical Rehabilitation Hospital, Viilor Street, No. 46-50, 400066 Cluj-Napoca, Romania"},{"name":"Department of Balneophysiokinetotherapy and Medical Recovery, Faculty of Nursing and Health Sciences, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, Victor Babe\u015f Street, No. 8, 400347 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41585-020-00382-9","article-title":"Sarcomatoid renal cell carcinoma: Biology, natural history and management","volume":"17","author":"Blum","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.6004\/jnccn.2017.0100","article-title":"Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Motzer","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clgc.2014.12.001","article-title":"Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma","volume":"13","author":"Kim","year":"2015","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00432-016-2304-3","article-title":"Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma","volume":"143","author":"Gu","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/j.clgc.2019.01.005","article-title":"Sarcomatoid renal cell carcinoma: Population-based study of 879 patients","volume":"17","author":"Alevizakos","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1016\/j.clgc.2017.12.005","article-title":"Treatments, outcomes, and validity of prognostic scores in patients with sarcomatoid renal cell carcinoma: A 20-year single-institution experience","volume":"16","author":"Korenbaum","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrurol.2015.232","article-title":"Gender differences in incidence and outcomes of urothelial and kidney cancer","volume":"12","author":"Lucca","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bju.12781","article-title":"A novel prognostic model for patients with sarcomatoid renal cell carcinoma","volume":"115","author":"Zhang","year":"2015","journal-title":"BJU Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"427.e17","DOI":"10.1016\/j.urolonc.2015.04.011","article-title":"Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation","volume":"33","author":"Adibi","year":"2015","journal-title":"Urol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1078-0432.CCR-20-2063","article-title":"Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"27","author":"Tannir","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11864-023-01161-5","article-title":"Treatment landscape of renal cell carcinoma","volume":"24","author":"Chen","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102734","DOI":"10.1016\/j.ctrv.2024.102734","article-title":"Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group","volume":"126","author":"Zatelli","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ferrari, S.M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M.R., Baldini, E., Ulisse, S., and Marone, G. (2019). Autoimmune endocrine dysfunctions associated with cancer immunotherapies. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102560"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/cncr.31200","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management","volume":"124","author":"Ott","year":"2018","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"pky021","DOI":"10.1093\/jncics\/pky021","article-title":"The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management","volume":"2","author":"Girotra","year":"2018","journal-title":"JNCI Cancer Spectr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: An updated review","volume":"9","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.euros.2024.10.002","article-title":"Trends and outcomes in sarcomatoid renal cell carcinoma: Analysis of the National Cancer Data Base","volume":"71","author":"Wang","year":"2025","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11934-026-01325-4","article-title":"Sarcomatoid renal cell carcinoma: Biological features and therapeutic implications\u2014A narrative review","volume":"27","author":"Lasorsa","year":"2026","journal-title":"Curr. Urol. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1515\/oncologie-2024-0637","article-title":"Novel insights into molecular landscape of advanced renal cell carcinoma","volume":"27","author":"Lucarelli","year":"2025","journal-title":"Oncologie"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"469.e19","DOI":"10.1016\/j.urolonc.2025.02.016","article-title":"Transcriptomic and proteo-metabolic determinants of the grading system in clear cell renal cell carcinoma","volume":"43","author":"Lucarelli","year":"2025","journal-title":"Urol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1097\/PAS.0000000000002233","article-title":"Sarcomatoid and rhabdoid renal cell carcinoma: Clinical, pathologic, and molecular genetic features","volume":"48","author":"Adeniran","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhi, H., Feng, M., Liu, S., Na, T., Zhang, N., and BiLiGe, W. (2020). Prognostic Significance of Sarcomatoid Differentiation in Patients With Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.591001"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"166.e21","DOI":"10.1016\/j.urolonc.2014.11.021","article-title":"Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent","volume":"33","author":"Merrill","year":"2015","journal-title":"Urol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2016.66.7931","article-title":"Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: A National Cancer Data Base study","volume":"34","author":"Hanna","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.clgc.2016.04.001","article-title":"Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: A systematic review with a meta-analysis","volume":"14","author":"Petrelli","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2014.05.034","article-title":"Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"66","author":"Heng","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/1097-0142(19870915)60:6<1313::AID-CNCR2820600625>3.0.CO;2-1","article-title":"Sarcomatoid renal cell carcinoma. A treatable entity","volume":"60","author":"Sella","year":"1987","journal-title":"Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-5347(05)64551-X","article-title":"Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: A phase II study of the Genitourinary Group of the French Federation of Cancer Centers","volume":"168","author":"Escudier","year":"2002","journal-title":"J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/cncr.20541","article-title":"Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma","volume":"101","author":"Nanus","year":"2004","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1007\/s12032-010-9649-2","article-title":"Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy","volume":"28","author":"Dutcher","year":"2011","journal-title":"Med. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s12032-011-9829-8","article-title":"A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802","volume":"29","author":"Haas","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/2326-6066.CIR-15-0150","article-title":"PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.19.01882","article-title":"Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and\/or sarcomatoid features","volume":"38","author":"McGregor","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cardona, Z., Sosman, J.A., Chandra, S., and Huang, W. (2023). Endocrine side effects of immune checkpoint inhibitors. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1157805"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"11617","DOI":"10.1038\/s41598-021-91032-6","article-title":"Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency","volume":"11","author":"Manaka","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens","volume":"4","author":"Barry","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/CJI.0000000000000299","article-title":"Nivolumab-induced adrenal insufficiency in patients with renal cell carcinoma","volume":"43","author":"Suzuki","year":"2020","journal-title":"J. Immunother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: A novel form of autoimmune diabetes","volume":"200","author":"Quandt","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hino, C., Nishino, K., Pham, B., Jeon, W.J., Nguyen, M., and Cao, H. (2022). Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.993622"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e001198","DOI":"10.1136\/jitc-2020-001198","article-title":"Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma","volume":"8","author":"Patel","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: Review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines\u00ae Insights: Management of immunotherapy-related toxicities, Version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"Farina","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e026407","DOI":"10.1161\/JAHA.122.026407","article-title":"Sacubitril\/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease","volume":"11","author":"Niu","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Lopes, A.C., Louren\u00e7o, O., Morgado, S., Gaspar, A., Freire, I., Eus\u00e9bio, I., Ribeiro, J., Silva, M., Mendes, M., and Fonseca, O. (2024). Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use. Pharmaceuticals, 17.","DOI":"10.3390\/ph17040420"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jemermed.2014.12.048","article-title":"Tetraparesis and failure of pacemaker capture induced by severe hyperkalemia: Case report and systematic review of available literature","volume":"48","author":"Sanson","year":"2015","journal-title":"J. Emerg. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJMra1704724","article-title":"Electrolyte disturbances in patients with chronic alcohol-use disorder","volume":"377","author":"Palmer","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/11\/1679\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:04:10Z","timestamp":1780070650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/11\/1679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":55,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["diagnostics16111679"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16111679","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}